Study to Evaluate the Efficacy and Safety of a Rilpivarine-based Antiretroviral Tratment Regimen in HIV- Infected Patients With Liver Metabolic Disease Who Maintain Udetectable HIV Viral Load
Conditions: HIV Infections; Fatty Liver Disease Interventions: Drug: Dolutegravir (DTG) 50 mg/day + Rilpivirine (RPV) 25mg per day; Drug: Tenofovir disoproxil fumarate (TDF) 245 mg per day or Tenofovir alafenamide (TAF) 25 mg per day + Emtricitabine (FTC) 200 mg per day + Rilpivirine 25 mg per day; Drug: Continue with their previous treatment. Any pre vious HAART that does not contain Rilpivirine. Sponsor: Fundacion SEIMC-GESIDA Recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
More News: Highly Active Antiretroviral Therapy | Liver | Research | Study | Truvada | Urology & Nephrology | Viread